Does the media prefer RXRX or STRO?

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 2 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 0.92 beat Sutro Biopharma's score of 0.67 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MAZE or STRO?

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.27 beat Sutro Biopharma's score of 0.67 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVBP or STRO?

In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 2 articles in the media. Sutro Biopharma's average media sentiment score of 0.67 beat ArriVent BioPharma's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STRO or XERS?

In the previous week, Xeris Biopharma had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Xeris Biopharma and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.67 beat Xeris Biopharma's score of 0.63 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STRO or SEPN?

In the previous week, Sutro Biopharma and Sutro Biopharma both had 2 articles in the media. Sutro Biopharma's average media sentiment score of 0.67 beat Septerna's score of 0.37 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sutro Biopharma (STRO) Competitors

$22.88 -0.52 (-2.23%)

As of 10:30 AM Eastern

Compare

STRO vs. RXRX, MAZE, AVBP, XERS, and SEPN

Should you buy Sutro Biopharma stock or one of its competitors? MarketBeat compares Sutro Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sutro Biopharma include Recursion Pharmaceuticals (RXRX), Maze Therapeutics (MAZE), ArriVent BioPharma (AVBP), Xeris Biopharma (XERS), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Sutro Biopharma has a net margin of -154.21% compared to Recursion Pharmaceuticals' net margin of -842.95%. Sutro Biopharma's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Sutro Biopharma	-154.21%	N/A	-69.20%

Sutro Biopharma has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	21.04	-$644.76M	-$1.20	N/A
Sutro Biopharma	$102.48M	3.69	-$191.09M	-$11.04	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Recursion Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Sutro Biopharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Recursion Pharmaceuticals currently has a consensus price target of $8.10, indicating a potential upside of 173.19%. Sutro Biopharma has a consensus price target of $52.44, indicating a potential upside of 129.67%. Given Recursion Pharmaceuticals' higher possible upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 2 articles in the media. Recursion Pharmaceuticals' average media sentiment score of 0.92 beat Sutro Biopharma's score of 0.67 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sutro Biopharma beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Maze Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Sutro Biopharma	-154.21%	N/A	-69.20%

Maze Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 136.59%. Sutro Biopharma has a consensus price target of $52.44, indicating a potential upside of 129.67%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Maze Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Maze Therapeutics has higher revenue and earnings than Sutro Biopharma. Maze Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.22	-$131.12M	-$2.53	N/A
Sutro Biopharma	$102.48M	3.69	-$191.09M	-$11.04	N/A

In the previous week, Maze Therapeutics and Maze Therapeutics both had 2 articles in the media. Maze Therapeutics' average media sentiment score of 1.27 beat Sutro Biopharma's score of 0.67 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Sutro Biopharma shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Maze Therapeutics beats Sutro Biopharma on 11 of the 14 factors compared between the two stocks.

How does Sutro Biopharma compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

ArriVent BioPharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Sutro Biopharma	-154.21%	N/A	-69.20%

ArriVent BioPharma has higher earnings, but lower revenue than Sutro Biopharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Sutro Biopharma	$102.48M	3.69	-$191.09M	-$11.04	N/A

ArriVent BioPharma presently has a consensus target price of $44.83, suggesting a potential upside of 46.08%. Sutro Biopharma has a consensus target price of $52.44, suggesting a potential upside of 129.67%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 2 articles in the media. Sutro Biopharma's average media sentiment score of 0.67 beat ArriVent BioPharma's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sutro Biopharma beats ArriVent BioPharma on 10 of the 15 factors compared between the two stocks.

How does Sutro Biopharma compare to Xeris Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Xeris Biopharma had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Xeris Biopharma and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.67 beat Xeris Biopharma's score of 0.63 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.69	-$191.09M	-$11.04	N/A
Xeris Biopharma	$291.85M	4.87	$550K	$0.06	137.25

Sutro Biopharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Sutro Biopharma's net margin of -154.21%. Xeris Biopharma's return on equity of 735.00% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Xeris Biopharma	3.81%	735.00%	3.24%

Sutro Biopharma presently has a consensus price target of $52.44, indicating a potential upside of 129.67%. Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 31.15%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Xeris Biopharma beats Sutro Biopharma on 10 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Septerna?

Sutro Biopharma (NASDAQ:STRO) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Septerna has lower revenue, but higher earnings than Sutro Biopharma. Septerna is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.69	-$191.09M	-$11.04	N/A
Septerna	$45.95M	32.97	-$48.88M	-$0.81	N/A

Sutro Biopharma presently has a consensus price target of $52.44, suggesting a potential upside of 129.67%. Septerna has a consensus price target of $45.89, suggesting a potential upside of 36.55%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Sutro Biopharma and Sutro Biopharma both had 2 articles in the media. Sutro Biopharma's average media sentiment score of 0.67 beat Septerna's score of 0.37 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sutro Biopharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

97.0% of Sutro Biopharma shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Septerna has a net margin of -49.88% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Sutro Biopharma beats Septerna on 8 of the 15 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$379.45M	$3.62B	$6.79B	$12.36B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-2.07	21.40	26.79	23.92
Price / Sales	3.69	302.63	575.42	114.33
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	-1.48	7.95	10.38	6.13
Net Income	-$191.09M	$23.81M	$3.60B	$331.73M
7 Day Performance	-3.77%	-1.64%	-1.74%	-1.24%
1 Month Performance	-21.77%	-1.77%	-0.62%	-2.53%
1 Year Performance	164.17%	33.78%	18.82%	14.67%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	2.9249 of 5 stars	$22.88 -2.2%	$52.44 +129.2%	+173.0%	$379.09M	$102.48M	N/A	240
RXRX Recursion Pharmaceuticals	3.4339 of 5 stars	$2.89 -1.7%	$8.10 +180.3%	-54.4%	$1.56B	$74.68M	N/A	400
MAZE Maze Therapeutics	2.0654 of 5 stars	$28.37 +0.9%	$66.00 +132.6%	+68.2%	$1.56B	$167.50M	N/A	121	Positive News
AVBP ArriVent BioPharma	2.2326 of 5 stars	$28.22 -15.0%	$44.83 +58.9%	+41.2%	$1.55B	N/A	N/A	40
XERS Xeris Biopharma	3.2964 of 5 stars	$8.60 -2.3%	$10.80 +25.6%	+63.7%	$1.52B	$291.85M	143.33	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. RXRX, MAZE, AVBP, XERS, and SEPN

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Summary

How does Sutro Biopharma compare to Maze Therapeutics?

Summary

How does Sutro Biopharma compare to ArriVent BioPharma?

Summary

How does Sutro Biopharma compare to Xeris Biopharma?

Summary

How does Sutro Biopharma compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. RXRX, MAZE, AVBP, XERS, and SEPN

How does Sutro Biopharma compare to Recursion Pharmaceuticals?

Is RXRX or STRO more profitable?

Which has higher earnings and valuation, RXRX or STRO?

Do insiders & institutionals believe in RXRX or STRO?

Which has more volatility and risk, RXRX or STRO?

Do analysts prefer RXRX or STRO?

Does the media prefer RXRX or STRO?

Summary

How does Sutro Biopharma compare to Maze Therapeutics?

Is MAZE or STRO more profitable?

Which has more risk and volatility, MAZE or STRO?

Do analysts prefer MAZE or STRO?

Which has preferable earnings & valuation, MAZE or STRO?

Does the media refer more to MAZE or STRO?

Do insiders & institutionals hold more shares of MAZE or STRO?

Summary

How does Sutro Biopharma compare to ArriVent BioPharma?

Which has more volatility & risk, AVBP or STRO?

Is AVBP or STRO more profitable?

Which has higher valuation & earnings, AVBP or STRO?

Do analysts rate AVBP or STRO?

Do institutionals & insiders have more ownership in AVBP or STRO?

Does the media prefer AVBP or STRO?

Summary

How does Sutro Biopharma compare to Xeris Biopharma?

Does the media favor STRO or XERS?

Which has stronger earnings & valuation, STRO or XERS?

Which has more risk & volatility, STRO or XERS?

Do insiders and institutionals hold more shares of STRO or XERS?

Is STRO or XERS more profitable?

Do analysts prefer STRO or XERS?

Summary

How does Sutro Biopharma compare to Septerna?

Which has preferable earnings and valuation, STRO or SEPN?

Do analysts recommend STRO or SEPN?

Does the media favor STRO or SEPN?

Which has more volatility and risk, STRO or SEPN?

Do insiders and institutionals have more ownership in STRO or SEPN?

Is STRO or SEPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools